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Abstract
Background: Malignant pleural mesothelioma is a rare disease known to be resistant to conventional therapies. A
better understanding of mesothelioma biology may provide the rationale for new therapeutic strategies. In this
regard, tumor cell lines development has been an important tool to study the biological properties of many
tumors. However all the cell lines established so far were grown in medium containing at least 10% serum, and it
has been shown that primary cell lines cultured under these conditions lose their ability to differentiate, acquire
gene expression profiles that differ from that of tissue specific stem cells or the primary tumor they derive from,
and in some cases are neither clonogenic nor tumorigenic. Our work was aimed to establish from fresh human
pleural mesothelioma samples cell cultures maintaining tumorigenic properties.
Methods: The primary cell cultures, obtained from four human pleural mesotheliomas, were expanded in vitro in a
low serum proliferation-permissive medium and the expression of different markers as well as the tumorigenicity in
immunodeficient mice was evaluated.
Results: The established mesothelioma cell cultures are able to engraft, after pseudo orthotopic intraperitoneal
transplantation, in immunodeficient mouse and maintain this ability to after serial transplantation. Our cell cultures
were strongly positive for CD46, CD47, CD56 and CD63 and were also strongly positive for some markers never
described before in mesothelioma cell lines, including CD55, CD90 and CD99. By real time PCR we found that our
cell lines expressed high mRNA levels of typical mesothelioma markers as mesothelin (MSLN) and calretinin
(CALB2), and of BMI-1, a stemness marker, and DKK1, a potent Wingless [WNT] inhibitor.
Conclusions: These cell cultures may provide a valuable in vitro and in vivo model to investigate mesothelioma
biology. The identification of new mesothelioma markers may be useful for diagnosis and/or prognosis of this
neoplasia as well as for isolation of mesothelioma tumor initiating cells.
Background
Malignant mesothelioma is an aggressive neoplasm arising
from the surface serosal cells of the pleural, peritoneal,
and pericardial cavities. Asbestos exposure has been estab-
lished as the primary cause of mesothelioma; however,
there is a long latency period of 30-45 years between expo-
sure to asbestos and development of disease. Workers in
the shipyard industry, insulation workers, construction
workers, and asbestos miners and manufacturers seem to
be at highest risk for developing the disease. Many investi-
gators have suggested that Simian virus 40 (SV40), origi-
nating from contaminated poliovirus vaccines that were
administered in USA and some European countries
between 50’sa n d7 0 ’s, might function as a cocarcinogen
involved in the development of the disease. However, the
relationship between SV40 and mesothelioma remains
uncertain [1]. Other findings suggest at least a cooperative
carcinogenic effect of SV40 and asbestos in mesothelioma
development [2,3]. The male to female ratio is about 4:1
[4]. Mesothelioma is a relatively rare disease. The inci-
dence of mesothelioma in Western Europe, and has been
steadily rising over the last 40 years, and now is of about
5000 cases per year. It is expected to reach a peak approxi-
mately in 2020, and the decrease over the next 50-60 years
as a result of the implementation of rules to reduce work-
place exposure to asbestos. Malignant pleural Mesothe-
lioma (MM) most commonly develops in the fifth to
seventh decade of life, with a median age of 60 years at
* Correspondence: giorgio.corte@istge.it
† Contributed equally
1Department of Oncology, Biology and Genetics, University of Genova,
Genova, Italy
Melotti et al. BMC Cancer 2010, 10:54
http://www.biomedcentral.com/1471-2407/10/54
© 2010 Melotti et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.diagnosis. The most common symptoms at diagnosis are
dyspnea and nonpleuritic chest pain. Several prognostic
factors have been identified in MM. Poor prognostic vari-
ables include: nonepithelial histology, older age (greater
than 75 years), pleural primary, chest pain at presentation,
poor performance status and elevated platelet count
(greater than 400,000/mcL). The median survival is in the
range of 4-18 months. Current therapies include surgery,
radiation therapy, chemotherapy, and multimodality ther-
apy, but have yielded disappointing results [5]. It is hoped
that a better understanding of MM biology may provide
the rationale for new therapeutic strategies. In this regard,
the development of tumor cell lines has been an important
tool to study the biological properties of many tumors.
However, only few mesothelioma cell lines have been
established [6-10]. There is no specific marker for
mesothelioma and antibodies that recognize molecules
expressed by mesothelial cells and mesothelioma have lim-
ited specificity.
A cancer stem cell population in malignant tumors
p l a y sa ne s s e n t i a lr o l ei nt u m or initiation, growth and
recurrence [11,12]. It was demonstrated that cancer stem
cells, capable of self-renewal and multilineage differentia-
tion, are present in blood and solid tumors [13-15]. This
clonogenic tumoral subpopulation is the only one able to
originate a tumor mass containing the variety of differen-
tiated cells present within the original tumor and, for this
reason, these cells were described as cancer stem cells.
This term may cause confusion, suggesting that the cell
of origin is a normal stem cell, a question still unresolved.
For this reason we prefer the term “tumor-initiating cells”
or TICs, as opposed to the non-tumorigenic cancer cells.
U n t i ln o wt h ep r e s e n c eo fT I C si nM Mt u m o r sh a s
not been demonstrated. Moreover all the primary cell
lines isolated so far were grown in medium containing
at least 10% serum, and it was demonstrated that pri-
mary cells cultured under these high serum conditions
lose their self-renewing properties, have no ability to dif-
ferentiate, exhibit gene expression profiles that are dif-
ferent from tissue specific stem cells or the primary
tumor they were derived from, and in some cases are
neither clonogenic nor tumorigenic [16].
To obtain a better MM in vitro and in vivo model, we
established MM cultures from fresh human pleural
mesothelioma surgical specimens. The primary cell lines
were expanded in vitro in a low serum proliferation-per-
missive medium and the expression of different markers
as well as the tumorigenicity in immunodeficient mice
was evaluated.
Methods
Patients and MM TICs culture
MM specimens were obtained from the Pneumology,
Spedali Civili (Brescia, Italy) and the Villa Scassi
Hospital (Genova Sampieradarena, Italy). Informed con-
sent was obtained for all patients as approved by the
Ethics Board. Pathologists diagnosed malignant
Mesothelioma. Of the 35-mesothelioma samples col-
lected 17 grew in vitro and only 4 in vivo. Two patients
included in this study were at an advanced stage of
MM, requiring only biopsy for the diagnosis. From two
patients was obtained a portion of the resected malig-
nant pleura sufficiently large to be able to undergo both
in vitro cell culture and a portion was fixed in 10% buf-
fered formalin and processed for the subsequent histolo-
gical analysis. Tumor samples were obtained in sterile
conditions avoiding apparently necrotic and fibrotic
areas. The 4 patients, all male, underwent surgery or
biopsy for the first time and never received chemother-
apy or radiotherapy; all the sample were diagnosed as
epithelioid MM. Tumor samples were immediately pro-
cessed by mechanical disgregation and plated on gelatin
coated flasks (Sigma, Saint Louis, MO, USA) in MCDB
(Sigma), 2 mM L-glutamine (Gibco Ltd, Paisley, Scot-
land), recombinant human bFGF (10 ng/ml, Peprotech,
London, UK), recombinant human EGF (20 ng/ml,
Peprotech), 15 μg/ml insulin, 2 μg/ml heparin and 2%
FBS (Euroclone, Devon UK). For subculture, 0.25% tryp-
sin-EDTA (Euroclone, Devon UK) was used. If stromal
cell growth was noted during initial growth, differential
trypsinization was used to obtain a pure tumor cell
population. The method is based on the treatment of
the culture with trypsin for around 1 minute, with con-
tinuous microscopic observation. When the fibroblasts
detach but the epithelial cells are still adherent the
enzyme is inactivated with FCS containing medium.
Pure populations of MM cells were obtained after three
to four passages. All cell cultures showed the monolayer
growth pattern, and population doubling times ranged
from 63 to 68 hours. Cultured cells were frozen in 10%
dimethylsulfoxide in fetal calf serum and stored in liquid
nitrogen. The four cell cultures were used between the
eighth and twelfth passage in culture.
Immunofluorescence
Cells of all patients were plated on gelatin coated glass
coverslips and then fixed with 4% paraformaldehyde,
treated with PBS 10% NGS 0.5% triton X100 and then
stained with the anti-SOX2 antibody (Chemicon,
Temecula, CA, USA) followed by goat anti-mouse IgG
(Alexa 488, Molecular Probes, Oslo, Norway) or rhoda-
mine-conjugated goat anti-rabbit IgG (Jackson Immu-
noResearch, West Grove, PA, USA). The cells were
counterstained with Hoechst 33342 dye (Sigma) to
identify nuclei.
Tumors cryosections were fixed in 4% PFA. Antibody
staining was carried out following heat induced antigen
retrieval using citrate buffer (pH 6.1) and with
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and blocked in 10% normal Goat serum-PBS. After
incubation with anti-Mesothelin antibody (Zymed
Laboratories, San Francisco, CA, USA), sections were
stained with the appropriate secondary antibodies and
counterstained with Hoechst 33342 dye (Sigma) to iden-
tify all nuclei.
MM xenografts and serial transplantation
10
3-10
6 MM primary cells were intraperitoneally (i.p.)
injected in 4-6 weeks old NOD-SCID mice (Charles
River, Milan, Italy) to test their ability to grow in vivo.
After several weeks cell growth was detected by the
development of obvious ascites. In-vivo grown cells
were harvested by intraperitoneal washing. A portion of
the above-recovered tumor cells were injected i.p. into
secondary NOD/SCID mice. Serial transplantation was
carried out every two months until the fifth passage,
using four mice per group. Mice were monitored for
disease symptoms and were sacrificed by CO2 asphyxia-
tion when ascites caused respiratory distress or they
became extremely weak. All experiments were per-
formed in compliance with guidelines approved by the
Ethical Committee for animal use in cancer research at
Istituto Nazionale Ricerca Cancro - Genova.
Immunohistochemical analysis
For xenograft tumor analysis, tumor masses grown in
vivo were collected from sacrificed mice, cryopreserved
and 10-μm cryostat (Leica, Wetzlar, Germany) sections
were cut. For WT-1 (Dako Cytomation, Denmark) stain-
ing, tumors cryosections were fixed in 4% PFA, treated
with 0.4% pepsin in 0.2 N HCl, then with 3% H2O2-PBS
protect from light, permeabilized in PBS 10% NGS 0.5%
Triton X-100, incubated with primary antibody and
then stained with anti-mouse EnVision-HRP (Dako).
Signal was revealed with AEC substrate (Sigma).
For Calretinin (Dako) staining, sections were fixed
in 4% PFA, then antibody staining was carried out fol-
lowing heat induced antigen retrieval using 10 mM
Tris-Cl 1 mM EDTA pH9 and treatment with 0.3%
H2O2-PBS protect from light. Cryosections were per-
meabilized in PBS 10% NGS 0.5% Triton X-100, incu-
bated with primary antibody and then with
biotynilated affinity-purified goat anti-mouse (BIOSPA,
Milano Italy). Expression was detected using streptavi-
din/horseradish peroxidase (Jackson Immunoresearch).
Signal was revealed with Chromogen 3-amino-9-ethyl-
carbazole (AEC) substrate.
For D2-40 staining (Dako), cryosections were fixed in
4% PFA, then antibody staining was carried out follow-
ing heat induced antigen retrieval using Target Retrival
Solution S1700 (Dako) and treatment with 3% H2O2-
PBS protect from light. Cryosections were permeabilized
in PBS 10% NGS 0.3% Triton X-100, incubated with pri-
mary antibody and then stained with anti-mouse EnVi-
sion-HRP and counterstained with Harris’s Ematossilin
(Bio-Optica). Signal was revealed with AEC substrate.
Mouse IgG was used as a negative control for all the tis-
sues. Digital images were captured by a Nikon Eclipse
80 i microscope (Nikon Europe, Lijnden, The
Netherlands).
Flow cytofluorimetric analysis
For cytofluorimetric analysis cultured MM cells were
stained with the appropriate amount of PE or FITC-
conjugated mAbs or PE or FITC- conjugated isotype-
specific control antibody. MM cells were stained with
the following antibodies: CD31, CD68, CD141, CD56,
CD63, CD86, CD30, CD11b, CD46, CD184, EGFR,
CD24, CD90, CD55, CD47, CD99, CD140b (BD
Bioscience, San Jose, CA). 10,000 labeled cells were
acquired and analyzed using a FACScan flow cytometer
running CellQuest software (Becton Dickinson & Co,
Mountain View, CA).
Real-Time PCR
Total RNA was isolated using RNeasy Mini Kit (Qiagen,
Milan, Italy), retrotranscribed using iScriptTM cDNA
Synthesis Kit (Bio-Rad, Milano, Italy) and amplified with
iQ Syber Green SuperMix (Bio-Rad) by PCR (iCYCLER,
Bio-Rad) using the following primers: Nanog (forward
5’gaactctccaacatcctgaacctc3’, reverse 5’ccttctgcgtcacac-
cattgc 3’), OCT4 (forward 5’tgtctccgtcaccactctg3’, reverse
5’ctttctgttcccaattccttcc3’), Sema3A (forward 5’ggcatataat-
cagactcacttgtacgc3’,r e v e r s e5 ’cttgcatatctgacctattc-
tagcgtg3’), NCAM2 (forward 5’agtggctccagtggcaaa3’,
reverse 5’ggctcccatcttcgtgatta3’), PDGFd (forward 5’aat-
gatgatgccaagcgttac3’,r e v e r s e5 ’gacctccagttgacagttcc3’),
ABCA6 (forward 5’ggcaggcaatccaggcagtc3’,r e v e r s e
5’acacggtcacacaaggcttcc3’), PDGFRb (forward
5’gtcctgcctgtccttctac3’,r e v e r s e5 ’tgtccttgctgctgatgg3’),
DKK1 (forward 5’agtccttctgagatgatgg3’,r e v e r s e
5’ggttcttgatagcgttgg3’), Mesothelin (MSTN) (forward
5’ggcacagaagaatgtcaag3’, reverse 5’atagcagcaggtccaatg3’),
calretinin (CALB2) (5’aacttccttctgtgcttc3’,r e v e r s e
5’tatggtttgggtgtattcc3’). Samples were normalized using
L41 primers (forward 5’agtggaggaagaagcgaatg3’, reverse
5’tttatgagcaaggtgggtctc3’). The four primary cell cultures
were analyzed together with positive and negative con-
trols. Data presented here are means of biological and
technical duplicates.
Cytogenetic analysis
Metaphases for cytogenetic analysis were prepared from
the first xenograft of the MM cell cultures. Chromo-
some preparations were obtained by standard cytoge-
netic techniques. For Q-banding metaphase spreads
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(Sigma-Aldrich) and counterstained with actinomycin D
(Sigma-Aldrich) [17] (Scheizer 1994). and karyotyped
according to the International System for Human Cyto-
genetic Nomenclature [18] (Shaffer LG, 2005) using the
Cytovision Karyotyping software (Applied Imaging,
Newcastle-upon-Tyne, UK).
Results
Establishment of human MM cell cultures
Seventeen of 35 original tumors could be cultured
under low-serum conditions, the remaining failing to
grow probably because of the reduced number of col-
lected cells. The new MM cell cultures were estab-
lished from 17 patients and have been maintained in
culture for up to 36 months. Plated cells exhibit poly-
gonal and epithelial-like shape under phase-contrast
microscope (Fig. 1A-D). They were successfully cul-
tured in a low serum proliferation-permissive medium
(see Materials and Methods) as spheres and as adher-
ent monolayers on gelatin-coated flasks. After thawing,
the cryopreserved cells were able to propagate in cul-
ture without noticeable change in growth and mor-
phology. The doubling time was evaluated at about 65
h. In all subsequent experiments the four cell cultures
were used between the fifth and twelfth passage in
culture.
In vivo growth of human MM cell cultures
To assess the tumorigenic properties of the MM cul-
tures, 10
3-10
6 MM primary cells were intraperitoneally
injected, within the fifth passage, in immunodeficient
NOD/SCID mice. Of the 17 established cell cultures
only four were able to grow in vivo, and were named
MM1 to MM4. After 3 to 6 months (Table 1), all cul-
tured cell tumors were generated with histological
properties resembling the primitive neoplasia. Animals
that received mesothelioma cells by i.p. injection devel-
oped moderate ascites; the vast majority of cells grew
as free-floating aggregates (Fig. 1E, F) and solid tumors
formed in the abdominal wall at the site of injection,
recapitulating the described ability of invasion through
the needle biopsy tract, typical features of malignant
mesothelioma [19,20], or in the retro gastric space;
peritoneal metastasis were seldom observed (Fig. 1G,
H). The mean survival time was 120 days for mice
injected with MM1 cells, 150 days for mice injected
with the MM2 cells, 210 days for mice injected with
the MM3 cells and 110 days for mice injected with
MM4 cells. Survival time was related to the number of
injected cells, as shown by the results obtained inject-
ing different numbers of MM1 cells, ranging from 10
3
to 10
6. For the lowest number of injected cells,
although the tumor take rate remained 100%, the sur-
vival time extended from 108 to 166 days. Cells iso-
lated from dissociated xenograft tumors and re-
cultured under stem cells conditions were able to form
spheres and, when injected back into new recipient
mice, not only retained the ability to generate new
tumors, but also showed an increased tumorigenic
potential, as shown by the shorter time required for
tumor development (Tab. 1).
Figure 1 In vitro and in vivo behavior of MM cells.A - D :
Morphological appearance of the MM1, MM2, MM3 and MM4 cell
cultures respectively. E, F: free floating aggregates recovered from
primary xenografts. Solid tumors grown in the abdominal wall at
the site of injection (G), or in the retro gastric space (H).
Table 1 Survival time of mice serially transplanted.
1
st transplant 2
nd transplant 3
rd transplant 4
th transplant
MM1 180 ± 20 130 ± 6 117 ± 3 76 ± 8
MM2 150 ± 16 122 ± 8 80 ± 5 70 ± 12
MM3 210 ± 28 105 ± 11 150 ± 15 41 ± 6
MM4 84 ± 8 92 ± 5
The four cell cultures were intraperitoneally injected into NOD/SCID mice (four
mice per group). Data show the mean survival time indicated as days.
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MM cells were injected into the peritoneal cavity of
NOD/SCID mice and tumor samples were collected for
immunohistochemical analysis. To confirm their
mesothelial origin, a panel of four markers typical of
mesothelioma was used: mesothelin, calretinin, D2-40
and WT-1. Xenografts were strongly positive for calreti-
nin and moderately positive for D2-40, mesothelin and
WT-1 (Fig. 2). This immunohistochemical profile is
diagnostic for human malignant mesothelioma. Cells
isolated from dissociated xenograft tumors and re-cul-
tured in a low serum proliferative-permissive medium,
are weakly positive for the same markers (data not
shown).
MM cells expression analysis
Cells recovered from the primary xenografts and cul-
tured for 3 to 5 passages, to deplete the possible con-
taminating mouse macrophages, were analyzed by FACS
for the expression of surface markers already known to
be expressed by mesothelioma cell lines or by other
kinds of neoplasias. All cell cultures were more than
90% positive for CD47, CD55 and CD99, between 65
and 95% for CD90 and CD46, between 30 and 92% for
CD56 and CD63, between 5 and 60% for CD140b,
between 0 and 20% for CD141. The cells were instead
negative or dim for CD11b, CD24, CD30, CD31, CD68,
CD86 and CD184 (CXCR4), (Fig. 3). Further gene
expression studies were performed by real time PCR on
the four MMs, in order to evaluate the cell type-specific
expression of various markers. MM cell cultures
expressed high mRNA levels of the mesothelioma mar-
kers mesothelin (MSLN), calretinin (CALB2), the
WNT1 antagonist DKK1 and the stem cell marker BMI-
1. The four cell cultures also express PDGFd, SEMA3A
and ABCA6 at intermediate levels and NCAM2 at low
levels (Fig. 4) but were negative for other stem cell mar-
kers such as SOX2, Nanog, Oct4 and CD133, (data not
shown).
Cytogenetic analysis
The karyotypes of the four cultures are reported in table
2. The karyotypes are hypodiploid (MM 4), hypotetra-
ploid (MM2 and MM3) or mixed hypodiploid and hypo-
tetraploid (MM1). All the karyotypes appeared very
rearranged. In most of the cases, the short arm of
Figure 2 MMs immunohistology. Solid tumors recovered from primary xenografts of the four MMs cell cultures stained with the indicated
antibodies. Negative controls for MM4 are included in the bottom row. Scale bar 100 μm.
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deleted or involved in rearrangements. In three cases
out of four the long arm of chromosome 6 is rearranged
as well as the long arm of chromosome 12. As far as
chromosome losses, in all cases chromosome 8, 14 and
15 are lost. The chromosome rearrangements distribu-
tion in the individual cultures demonstrate an oligoclo-
nal composition.
Discussion
The development of tumor cell lines has been an impor-
tant tool in establishing suitable in vitro models for
studying the biological properties of many tumors. All
mesothelioma cell lines derived so far were established
in-high serum growth media. Tumor cells expanded
under such conditions, however, often display phenoty-
pic characteristics and genetic aberrations due to the
long term in vitro culture in the presence of calf serum
and are very different to those found within the corre-
sponding primary human tumor, also in their gene
expression profile.
We have derived and characterized four human
mesothelioma cell cultures that retain tumor initiating
cell properties, using the chemically defined medium
MCDB201 supplemented with 2% FCS, EGF and FGF. A
low serum medium and selected mitogens were used for
their known ability to encourage self-renewal by pre-
venting in vitro commitment to differentiation, and to
preserve the ability to form tumors in immunodeficient
mice that recapitulate the heterogeneity normally seen
on human cancers [16,21].
The growth and morphological properties of these
new established mesothelioma cell cultures are hetero-
geneous. Some of them grow as fairly firmly attached
monolayers whereas others grow as both floating and
loosely attached cultures.
The MM1-4 cell cultures described here are able to
engraft after pseudo orthotopic intraperitoneal trans-
plantation in immunodeficient mouse, where they
mainly grow as free floating cells that eventually aggre-
gate, recapitulating a characteristic that is thought to be
typical of normal mesothelial stem/progenitor cells [22].
When as low as 1000 cells were injected the tumor take
rate was not affected, indicating that our cell cultures
are highly enriched in tumor initiating cells when com-
pared to the other available MM cell lines, which
require at least 10
6 cells to obtain the same take rate
[23]. Their ability to engraft after serial transplantation
is a hallmark of tumor initiating cells. The faster devel-
opment of tumor after serial transplantation may be due
Figure 3 In vitro and in vivo behavior of MM cells.M Mc e l l s
recovered from primary xenografts were analyzed by FACS for the
expression of the indicated molecules using the appropriate
amount of PE or FITC-conjugated mAbs. Grey profiles refer to cells
incubated with PE or FITC- conjugated isotype-specific control
antibody.
Melotti et al. BMC Cancer 2010, 10:54
http://www.biomedcentral.com/1471-2407/10/54
Page 6 of 9to a progressive increase of the TICs fraction or to an in
vivo selection of the more aggressive cells. To avoid this
selection of fast proliferating cells and to completely
deplete the contaminating fibroblasts present in primary
cultures, all the experiments were performed with cells
recovered from the first xenograft. To determine
whether MM cell cultures display genomic alterations
characteristic of mesothelioma, we performed cytoge-
netic analyses of the cell cultures recovered from pri-
mary xenografts. The results confirmed their human
origin and showed many and varied structural and
numeric abnormalities. The disease develops for dec-
ades, during which the neoplastic cells accumulate a
variety of chromosomal aberrations. Cytogenetic analysis
revealed rearrangement of the short arm of chromosome
1, an aberration frequently reported in mesothelioma
karyotypes (56% of the cases), as well as rearrangements
of the short arm of chromosome 3 that are found in
51% of the cases, deletion accounting for nearly half of
them (48%)[24]. Sandberg and Bridge [25] proposed a
scheme for the stepwise process of genetic changes lead-
ing to the full development of malignant mesothelioma.
In this scheme a deletion in the short arm of chromo-
some 3 is a late event and deletion of chromosome 1 is
mainly found in metastatic tumors.
In order to better characterize the MM cell cultures
we performed a phenotypic characterization by FACS
analysis using antibodies against membrane proteins.
Among the surface markers known to be expressed by
mesothelioma cell lines, our cell cultures were strongly
positive for CD46 [26], CD47 [27], CD56 [28] and CD63
[29], while showed a variable positivity for CD140b [30]
and CD141 [31]. The four MM cell cultures were also
strongly positive for some markers never described
before in mesothelioma cell lines, including CD55,
CD90 and CD99 that may represent new markers
potentially useful for the isolation of cancer stem cells
from MM. CD55 together with CD46 are complement
regulatory proteins. Cells that express complement regu-
latory proteins are able to modulate their sensitivity to
complement-mediated lysis and their ability to survive
into a proinflammatory environment in which C3 activa-
tion frequently occurs. It has been demonstrated that a
reduction in CD46 results in increased C3b deposition
on apoptotic cells, which are then killed by macro-
phages. The complement-regulatory proteins are also
able to regulate T cell function inhibiting the immune
response against cancer. CD55 was also found expressed
on side-population (SP) cells of mammary carcinoma
cell lines and used for isolation of cancer stem cells.
Cells expressing high level of CD55 were resistant to
apoptosis induced by serum depletion as in the case of
SP cells. The identification of CD90 on our cells, a mar-
ker known to be expressed on subsets of hematopoietic
and non-hematopoietic stem cells, raises the possibility
that CD90 expression identifies a highly proliferative
and/or stem cell-like component of these neoplasm.
CD90 is also expressed on mesenchymal stem cells and
fibroblasts not committed to adipogenesis.
Figure 4 MMs Real Time PCR. Expression of indicated genes
analyzed by qRT-PCR. Data are shown as ratio between the
indicated gene and an housekeeping gene (L41). Bars indicate the
Standard Deviation, values on Y axis are in log-scale.
Table 2 Q-banding karyotypes of the four MM cell cultures recovered form primary transplants.
MM1 39-40, XY dic(1;4)(p12;q31), t(1;19)(p13;p13.1),2, del(2)(p21), del(3)(p14), del(3)(q13), del(6)(q14q22),-8, del(10)(q2425), der(11)t(11;18)(q23;q11.2),
der(12)t(12;?)(q22;?), -13,-13,-14,-15,-17,-18,-18,+4-5 m [3cp]; 76-77, XXYY idemx2 [2cp]
MM2 71-102, XXY der(1)dup(p13p32)inv(q12p33)x2,-2, t(3;?)(p0;?), i(3q),-4,+5,-8, del(9)(p21),-9,11, der(12) del(12)(p13)t(12;?)(q24;?)x2, der(13)t(13;?)
(p0;?),-13,-14,-15,-16,-17,-18,-19-20,-21,+10 m [4cp]
MM3 58-78, XX-Y, i(1)(q0),-1, der(3)t(3;12)(q0;p0), del(4)(q32),-4,-5, del(6)(q16q21), -6,-7,-8,-9, del(10)(q24q26),+11,-12,-13,-14,-15,-16,-18,-22,+5-10 m
[5cp]
MM4 36-37, XY del(1)(p32), t(1;11)(p32;q22)dup(11)(q14q22), del(3)(p21), t(3;22)(q11.2;q13),-4,-5, add(6) (q27),-8,-9,-9,+der(12)dup(12)(q21),-14,-14,-15,-
15,-16,-17,17, i(18q), der(19)t(19;?)(q13.2;?), add(21)(p12),+1-6 m [3cp]
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malignant melanoma, in pancreatic endocrine tumors,
Ewing’s sarcoma and gastric cancer. A splice variant of
CD99 increases motility and MMP-9 expression of
human breast cancer cells, in osteosarcoma and prostate
cancer. In osteosarcoma and prostate cancer, cells over-
expressing the long CD99wt isoform inhibited and
delayed formation of lung or bone metastases. The high
level of CD99 on MM cells may explain the absence of
long distance metastasis.
CD140b (PDGFRb) is of special interest since the a
subunit of the receptor is predominantly expressed in
benign mesothelial cells, whereas expression of the b
subunit is found in MM cell lines and clinical specimens
[32]. An inverse correlation between the expression of
PDGFRb and PDGFd was observed on our MM cells.
This observation suggests that cells expressing low levels
of receptor needs to produce high levels of ligand, sup-
porting the importance of this autocrine pathway in
MM, a possible therapeutic target.
By real time PCR we found that our cell cultures
expressed high mRNA levels of typical mesothelioma
markers as mesothelin (MSLN) and calretinin (CALB2),
of BMI-1, a stemness marker and of DKK1, a potent
Wingless [WNT] inhibitor. It is interesting to note that,
i nap r e v i o u sr e p o r t[ 3 3 ] ,D K K 1w a su s e dt oi n d u c e
apoptosis of MM cells by antagonizing Wnt signaling
independently of b-catenin. Our cell cultures express
DKK1 at high levels, like other tumors such as Wilms’
tumor, osteosarcomas, hepatocellular carcinomas and
prostate cancer [34-36]. It is already known that Wnt
signaling is an osteoinductive signal that promotes dif-
ferentiation of osteo-progenitors and that, in human
mesenchymal stem cell the inhibition of Wnt signaling
with recombinant soluble DKK1 induces spontaneous
transformation and tumorigenicity [37]. Other reports
indicates that sustained Wnt signaling inhibits neural
differentiation while inducing differentiation along
meso/endoderm lineages in human and mouse embryo-
nic stem cells [38]. It is therefore conceivable to
hypothesize that mesothelium belongs to the develop-
mental lineage group of cells that are induced to differ-
entiate by Wnt signaling. Thus, the inhibitory effect of
DKK1 would maintain stemness and inappropriate per-
sistent DKK1 and BMI-1 expression would ultimately
lead to malignant transformation, by keeping the cells in
an undifferentiated, “stem-like” cellular state.
Conclusions
In conclusion, this paper describes the establishment
and characterization of four new mesothelioma cell cul-
tures derived from male patients that never received
chemotherapy or radiotherapy. Our cells, cultured under
stemness conditions, are able to survive and grow in low
serum conditions, although at a slower rate than that
observed under high serum conditions. When trans-
planted into immunodeficient mice these cells are able
to engraft and form tumors that are phenocopies of the
original tumor. The cells expressed mesothelioma mar-
kers together with some typical genes involved in stem-
ness such as BMI-1 and CD90. The expression of these
stem cell markers may reflect the presence in these cul-
tures of a higher proportion of TICs compared to the
mesothelioma cell lines available to date which have
been kept in high serum media and passaged for long
periods. This higher “stemness” is supported by the fact
that 10
3 cells are able to achieve 100% tumor take, a
thousand-fold less than required by the other available
MM cell lines. For these reasons, these MM cell cultures
may provide a valuable in vitro and in vivo model to
study the biology of this poorly understood deadly
tumor.
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